Back to top

messenger-rna: Archive

Zacks Equity Research

FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy

An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.

PFENegative Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXPositive Net Change

Zacks Equity Research

Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

PFENegative Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXPositive Net Change

Zacks Equity Research

Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea

Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.

PFENegative Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXPositive Net Change

Zacks Equity Research

Moderna (MRNA) Up on Upbeat Data From Phase III Study on RSV Jab

Data from a late-stage study showed that Moderna's (MRNA) RSV vaccine was 83.7% effective at preventing at least two symptoms in adults aged 60 and older.

GSKNegative Net Change PFENegative Net Change MRNAPositive Net Change ALLOPositive Net Change

Zacks Equity Research

Moderna (MRNA) Reports 2023 Business View & Pipeline Updates

Moderna (MRNA) expects to record a minimum of $5 billion in revenues from COVID vaccine sales in 2023. It also expects to incur around $4.5 billion as R&D expenses in 2023.

MRKPositive Net Change VRTXPositive Net Change MRNAPositive Net Change ALLOPositive Net Change

Zacks Equity Research

FDA Accepts Pfizer's (PFE) sBLA Filing for Pneumococcal Jab

The FDA grants priority review to Pfizer's (PFE) filing seeking label expansion of its pneumococcal 20-valent conjugate vaccine in infants and children. A decision is expected by this April.

SNYPositive Net Change PFENegative Net Change NVOPositive Net Change MRKPositive Net Change

Zacks Equity Research

CytomX (CTMX) Up 55% on Strategic Partnership With Moderna

CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.

REGNPositive Net Change MRNAPositive Net Change ABBVPositive Net Change CTMXPositive Net Change